Loading organizations...
ATMI, Inc. developed and supplied advanced process materials, chemicals, and specialized materials-handling solutions crucial for high-tech manufacturing. The company’s offerings included purification systems, specialty chemicals, and equipment, which were integral to enhancing processes within the semiconductor, flat panel display, and life sciences industries, focusing on improving yields and performance in these critical sectors.
The company was founded in 1986 by Dr. Eugene G. Banucci, alongside a team of scientists. Their insight stemmed from recognizing unmet needs in the precision material and process technology landscape, particularly for the burgeoning microelectronics industry. Dr. Banucci led ATMI as CEO and Chairman, guiding its growth from inception until its acquisition.
ATMI's products were utilized globally by manufacturers striving for efficiency and innovation in producing advanced electronic components and biotechnological applications. The company’s long-term vision was to remain an indispensable partner, continually advancing the materials and processes that underpinned its customers’ most sophisticated production demands, ultimately becoming a leading supplier of critical technology solutions.
ATMI has 1 tracked investment across 1 company. The latest tracked deal is $31.4M Debt / Series B in Promethera Biosciences in March 2012.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 28, 2012 | Promethera Biosciences | $31.4M Debt / Series B | — | Boehringer Ingelheim, Financière Spin OFF Luxembourgeoise, Life Sciences Research Partners, Mitsui & CO. Global Investment, Nivelinvest, Sambrinvest, Shire, Sopartec, Sriw, Vesalius Biocapital, Vives Louvain Technology Fund, Walloon Region |